Trial Profile

The effects of sacubitril/valsartan compared to valsartan on left ventricular remodelling in patients with asymptomatic left ventricular systolic dysfunction after myocardial infarction: a randomised, double-blinded, active-comparator, cardiac-MR based trial.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sacubitril/valsartan (Primary) ; Valsartan
Indications Heart failure; Left ventricular dysfunction; Myocardial infarction
Focus Proof of concept; Therapeutic Use
Acronyms RECOVER-LV

13 May 2021 Primary endpoint (Left ventricular end systolic volume) baseline to 52-weeks has not been met. according to the results published in the Circulation.
13 May 2021 Results assessing the comparison of sacubitril/valsartan with valsartan in patients with myocardial infarction (MI) and asymptomatic left ventricular systolic dysfunction (LVEF), published in the Circulation.
10 Aug 2020 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com